ALK and lung adenocarcinoma: With this background it appears unsurprising that in LTS patients, targetable alterations are much more frequent than among non-selected patients with adenocarcinoma of the lung (EGFR: 41 vs. 11%; ALK: 8 vs. 4.8%) [22, 36].